Merck KGaA in licensing deal with Nerviano Medical for PARP inhibitor

Merck KGaA in licensing deal with Nerviano Medical for PARP inhibitor

Submitted by admin on September 21, 2022 - 8:01pm
Source: 
Seeking Alpha
News Tags: 
Merck KGaA
Nerviano Medical Sciences
NS-293
PARP inhibitors
Headline: 
Merck KGaA in licensing deal with Nerviano Medical for PARP inhibitor
snippet: 

Merck KGaA (OTCPK:MKKGY) has brokered a licensing agreement with Nerviano Medical Sciences gaining access to NMS-293, a next-generation highly selective and brain-penetrant PARP1 inhibitor.

Do Not Allow Advertisers to Use My Personal information